Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
AORT submitted a Form 144 notice disclosing a proposed sale of 2,784 common shares with an aggregate value of $105,861.32. The filing lists the transaction type as Restricted Stock Vesting and shows the sale notice dated 03/02/2026.
The form also records recent dispositions by John E. Davis of 3,773 shares on 02/23/2026 and 2,075 shares on 02/24/2026, with aggregate amounts shown for each sale.
Amy D. Horton reported proposed sales of common stock under a Form 144. The filing lists a restricted stock vesting event of 641 shares on 02/27/2026 described as issuer compensation and multiple sales during the prior three months: 4,572 shares on 12/08/2025, 1,731 shares on 02/23/2026, and 830 shares on 02/24/2026.
The broker of record shown is Fidelity Brokerage Services LLC and the filing references a transaction date of 03/02/2026.
AORT Form 144: a notice of proposed and recent sales of Common stock. The filing lists a proposed sale tied to Restricted Stock Vesting on 02/27/2026 for 5,178 shares. It also reports prior sales by Lance Berry of 4,981 shares on 02/23/2026 for $187,223.34 and 4,485 shares on 02/24/2026 for $160,082.66.
AORT insider filings report proposed and completed transactions in common stock. The filing lists a restricted stock vesting of 1,513 shares on 02/27/2026 described as issuer compensation. It also reports past sales by Marshall S. Stanton of 2,423 shares for $91,074.51 on 02/23/2026 and 1,259 shares for $44,937.36 on 02/24/2026.
ARTIVION, INC. executive Amy Horton, VP and Chief Accounting Officer, reported both stock sales and a stock grant. On February 23, 2026, she sold 1,731 shares of common stock at $37.588 per share, and on February 24, 2026, she sold 830 shares at $35.693 per share.
According to the footnotes, both sales were automatic "sell to cover" transactions to pay tax withholding upon vesting of performance and restricted stock units, and did not represent discretionary trades. Horton also received a grant of 5,658 shares of restricted stock at no cost, which vest in three equal annual installments, and held 133,155 shares directly after these transactions.
Artivion, Inc. SVP Stanton Marshall S. reported two open-market sales of common stock that were executed solely to cover tax withholding on vesting equity awards. On February 23, 2026, he sold 2,423 shares at an average price of $37.588 per share. On February 24, 2026, he sold an additional 1,259 shares at an average price of $35.693 per share. The footnotes state these were "sell to cover" transactions to satisfy tax obligations and did not represent discretionary trading decisions. After the latest transaction, he directly owned 41,921 common shares.
Artivion, Inc. senior vice president and general counsel Jean F. Holloway reported both stock sales and an equity award in company shares. On February 23–24, 2026, she sold a total of 4,747 shares of common stock at prices of $37.588 and $35.693 per share.
Footnotes state these sales were automatically executed to cover tax withholding owed upon vesting of performance and restricted stock units, and are not discretionary trades. She also received a grant of 20,085 shares of restricted stock at no cost, which vest in three equal annual installments starting on the first anniversary of the grant date.
ARTIVION, INC. President & CEO James P. Mackin reported both automatic tax-related sales and an equity award of common stock. On February 23–24, he sold a total of 34,898 shares at prices around $35.69–$37.59 in pre-arranged “sell to cover” transactions to pay tax withholding on vesting performance and restricted stock units, which the company notes were not discretionary trades. On February 24, he also received a grant of 97,030 shares of restricted stock at no purchase price, vesting 33 1/3% per year starting on the first anniversary of the grant under the Equity and Cash Incentive Plan. Following these transactions, Mackin directly holds 863,125 shares of Artivion common stock.
Artivion, Inc. executive Lance A. Berry reported routine equity compensation activity. On February 23 and 24, he sold 4,981 and 4,485 shares of common stock at $37.588 and $35.693 per share, respectively, to cover tax withholding triggered by vesting of performance and restricted stock units, which the company notes were non-discretionary “sell to cover” transactions.
On February 24, he also acquired a grant of 37,482 shares of restricted stock at no cost, which vest in equal thirds annually starting on the first anniversary of the grant date under the Equity and Cash Incentive Plan. Following these transactions, his directly held common stock increased to 181,447 shares.
Artivion, Inc.’s Chief Commercial Officer John E. Davis reported a mix of stock compensation activity and related tax sales. He received a grant of 20,438 shares of restricted stock, which vest in equal thirds each year starting on the first anniversary of the grant date.
To cover tax withholding from vesting performance and restricted stock units, 5,848 shares were automatically sold in open-market transactions at prices of about $35.69 and $37.59 per share, described as non-discretionary “sell to cover” sales. After these transactions, Davis directly owns 209,306 shares of common stock.